Miransertib (ARQ 092) HCl is primarily used in the field of oncology as a targeted therapy for the treatment of cancers associated with mutations in the AKT1 gene. It functions as an AKT inhibitor, effectively blocking the PI3K/AKT/mTOR signaling pathway, which is often hyperactive in various cancers. This inhibition helps to reduce tumor growth and progression, making it a promising option for patients with specific genetic mutations. Additionally, it is being explored for its potential in treating Proteus syndrome, a rare overgrowth disorder caused by AKT1 mutations. Its ability to selectively target abnormal cellular pathways offers a more precise and potentially less toxic treatment approach compared to traditional chemotherapy.